1. Nanopharmaceutics in immunology: what's new in research?
Ranjita Shegokar, Ana Rita Fernandes and Eliana Souto
2. Skin delivery of antimicrobial peptides
Monika Schaefer-Korting and Jens Rolff
3. Skin penetration of nanoparticles
Shohreh Nafisi and Howard I. Maibach
4. Regulatory and risk assessment perspective for Core-Multishell Nanocarriers: A novel excipient on its way towards marketing authorization
Sam D. More, Margret More, Florian Paulus, Emanuel Fleige amd Marcin Libera
5. Anti-inflammatory drugs: Pharmaceutical Nanotechnology approach
Andjelka B. Kovačevic, Sergio M.C.Silva and Slavomira Doktorovova
6. New strategies for the treatment of auto-immune diseases using nanotechnologies
Amelia M. Silva, Joao R. Siopa, Carlos Martins-Gomes, Maria C. Teixeira, Dario J. Santos, Maria dos Anjos Pires and Tatiana Andreani
7. Nanopharmaceutics Applications in Inhaler Systems
Aysu Yurdasiper, Mesut Arici and Mine Ozyazici
8. Immunomodulatory Effects of Curcumin in infectious and non-infectious diseases
9. Advances in Antibiotic Nanotherapy: Overcoming Antimicrobial Resistance
Teixeira, M.C., Sanchez-Lopez, E., Espina, M., Calpena, A.C., Silva, A.M., Veiga, F.J., Garcia, M. L., Souto, E.B.
The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body. This book aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanopharmaceuticals currently in the pipeline of S&T development for skin, ocular and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure.
The contributors address a representative set of the broad spectrum of nanopharmaceutics presently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue-engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanopharmaceuticals still represents a barrier to their wide innovative use.
- Provides a thorough knowledge of the safety aspects of nanopharmaceuticals currently under research
- Focuses on the characterization and quantification of nanopharmaceutics to allow readers to understand the correlation between the nature of the materials and their potential nanotoxicological effects
- Includes a thorough overview of legal and regulatory aspects and a discussion of the ethical issues related to the R&D of nanopharmaceuticals
Academics, researchers and scientists, as well as post-graduates, developing their research in the area of Topical Drug Delivery; Policy makers and pharmaceutical companies and learned societies, associations and research groups working in topical nanopharmaceuticals
- No. of pages:
- © Elsevier 2018
- 1st May 2018
- Hardcover ISBN:
Dr. Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India and has been postdoctoral researcher at Free University of Berlin, Department of Pharmaceutical Technology, Biopharmaceutics and NutriCosmetics, Berlin, Germany. Since last 6 years she is working for pharmaceutical industry in various technical / R & D roles. Currently, she serves as Head of Formulation Development department at Symrise AG, Germany. Dr. Shegokar has authored more than 45 research articles, 20 book chapters and 150 research abstracts. She has filed two patent applications on nanoparticles for targeting malaria and HIV/AIDS reservoirs and have 2 other application in area of active delivery. She is a recipient of several national and international awards for her research. Her areas of interest are oral solid dosage forms, dermal formulations, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions and galenic formulations.
Head of Formulation Development department at Symrise AG, Germany.
Eliana B. Souto is Assistant Professor of Pharmaceutical Technology at the Faculty of Health Sciences in University Fernando Pessoa in Porto, Portugal. In her home University she coordinates the Biopharmaceutical Chemistry Unit of the Doctoral Programme in Biotechnology and Health, and the EuroPhD in Advanced Drug Delivery from Galenos Network. She also belongs to the Institute for Biotechnology and Bioengineering, Centre of Genetic and Biotechnology. Eliana B. Souto is graduated in Pharmaceutical Sciences from the Faculty of Pharmacy, University of Coimbra. She also obtained a post-graduated Master degree in Pharmaceutical Technology and Pharmacotechnique at the Faculty of Pharmacy, University of Porto, and awarded with the degree of PhD in Pharmaceutical Technology, Biopharmaceutics and Biotechnology at the Institute of Pharmacy, Free University of Berlin, Germany. Her research group is devoted to the design, development, and characterization of lipid nanocarriers for controlled delivery of drugs across biological barriers, namely skin, gastrointestinal tract, blood-retinal and blood-brain barriers. Eliana is member of the Editorial Board of several other peer-reviewed scientific journals, author and co-author more than 70 full-length published SCI articles, 15 book chapters, 150 abstracts and/or proceedings published in national and international meetings.
Assistant Professor of Pharmaceutical Technology, Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal